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Mitochondrial Trifunctional Protein (MTP)Over the last years acylcarnitines have emerged as important biomarkers for the diagnosis of mitochondrial
fatty acid β-oxidation (mFAO) and branched-chain amino acid oxidation disorders assuming they reﬂect the
potentially toxic acyl-CoA species, accumulating intramitochondrially upstream of the enzyme block.
However, the origin of these intermediates still remains poorly understood. A possibility exists that carnitine
palmitoyltransferase 2 (CPT2), member of the carnitine shuttle, is involved in the intramitochondrial
synthesis of acylcarnitines from accumulated acyl-CoA metabolites. To address this issue, the substrate
speciﬁcity proﬁle of CPT2 was herein investigated. Saccharomyces cerevisiae homogenates expressing human
CPT2 were incubated with saturated and unsaturated C2–C26 acyl-CoAs and branched-chain amino acid
oxidation intermediates. The produced acylcarnitines were quantiﬁed by ESI-MS/MS. We show that CPT2 is
active with medium (C8–C12) and long-chain (C14–C18) acyl-CoA esters, whereas virtually no activity was
found with short- and very long-chain acyl-CoAs or with branched-chain amino acid oxidation
intermediates. Trans-2-enoyl-CoA intermediates were also found to be poor substrates for CPT2. Inhibition
studies performed revealed that trans-2-C16:1-CoA may act as a competitive inhibitor of CPT2 (Ki of
18.8 μM). The results obtained clearly demonstrate that CPT2 is able to reverse its physiological mechanism
for medium and long-chain acyl-CoAs contributing to the abnormal acylcarnitines proﬁles characteristic of
most mFAO disorders. The ﬁnding that trans-2-enoyl-CoAs are poorly handled by CPT2 may explain the
absence of trans-2-enoyl-carnitines in the proﬁles of mitochondrial trifunctional protein deﬁcient patients,
the only defect where they accumulate, and the discrepancy between the clinical features of this and other
long-chain mFAO disorders such as very long-chain acyl-CoA dehydrogenase deﬁciency.β-oxidation; CPT1, carnitine
nsferase 2; CACT, carnitine/
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Mitochondrial fatty acid β-oxidation (mFAO) is the most impor-
tant source of energy, especially for high-energy demanding tissues
such as the heart and skeletal muscle [1]. In order to bemetabolized in
themitochondria, long-chain fatty acids must ﬁrst undergo activation,
prior to its transport into the mitochondrial matrix. The import of
activated long-chain fatty acids (long-chain acyl-CoAs) into themitochondrial matrix is handled by the carnitine shuttle. This system
operates by the combined action of carnitine palmitoyltransferase 1
(CPT1, EC 2.3.1.21), carnitine/acylcarnitine translocase (CACT,
SLC25A20) and carnitine palmitoyltransferase 2 (CPT2, EC 2.3.1.21)
and requires the presence of L-carnitine. Long-chain acyl-CoA esters
are ﬁrst converted into the corresponding carnitine esters by CPT1,
followed by transport of the resulting acylcarnitines across the
mitochondrial membrane by CACT, located in the inner mitochondrial
membrane, in exchangewith free carnitine. The ﬁnal step of this cycle,
catalyzed by CPT2, reconverts the acylcarnitines back into the
respective acyl-CoA esters that can then undergo β-oxidation [2–4].
During fasting or when the energy demand is increased, fatty acid
oxidation is crucial for cellular energy homeostasis. Pathologies involving
one or several defects of themitochondrial fatty acid β-oxidation system,
especially those concerning long-chain fatty acids, are complex and
clinically heterogeneous. Affected patients usually present hypoketotic
hypoglycemia with hepatic, cardiac and muscular symptoms [5,6]. In
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affecting long-chain mFAO such as deﬁciencies at the level of very long-
chain acyl-CoA dehydrogenase (VLCAD), long-chain 3-hydroxyacyl-CoA
dehydrogenase (LCHAD) and mitochondrial trifunctional protein (MTP)
tend to bemore severe and present unusual features. Such complications
may be caused by the accumulation of toxic intermediates as a
consequence of the impaired β-oxidation of long-chain fatty acids [6,7].
An impairment in mFAO, as in genetic FAO deﬁciencies, gives rise to the
intracellular accumulationof acyl-CoAs and itsβ-oxidation intermediates,
which may be further metabolized by alternative oxidative pathways,
such as ω and ω−1 oxidation, leading to the production of dicarboxylic
acids and/or elimination as acylglycines and/or acylcarnitines with
secondary L-carnitine depletion. Acylcarnitines are currently used in
neonatal screening programs as biomarkers for the diagnosis of mFAO
disorders. Nevertheless, the etiology of these acylcarnitines is still not
completely elucidated. It is usually considered that the observed
acylcarnitine proﬁles reﬂect the intramitochondrially accumulating
acyl-CoAs which are exported out of the mitochondria as their
correspondent carnitine esters [8,9].
It is hypothesized that the acylcarnitines are formed by carnitine
palmitoyltransferase 2, although formal proof is lacking for most of
the acyl-CoAs. This would be followed by the export of these
acylcarnitines from the mitochondria and the cell, processes not yet
deﬁnitively clariﬁed. Some work has been done pointing towards
reversibility of the physiologic mechanism of the carnitine shuttle
[10,11]. However the lack of a comprehensive study on this subject
and speciﬁcally on human CPT2 prompted us to investigate the
complete substrate speciﬁcity of this enzyme. The data described in
this paper provides new insights into the speciﬁc role of CPT2 in the
export of toxic acyl-CoAs from the mitochondria into the cytosol and
subsequently into the extracellular space.
2. Materials and methods
2.1. Strains of Saccharomyces cerevisiae and growth media
TheΔcat2 (cat2::KAN) andΔfox2 (fox2::KAN)deletionmutants of S.
cerevisiae strain BY4742 (Matα; his3Δ1; leu2Δ0; lys2Δ0; ura3Δ0) were
used. The strain was cultured in rich glucose medium, YPD (glucose
20 g/l, peptone 20 g/l and yeast extract 10 g/l) and minimal glucose
medium, YNBD (glucose 3 g/l or 20 g/l and yeast nitrogen basewithout
amino acids 6.7 g/l). For plates, agar 20 g/l was added. Galactose
medium contained yeast extract 1 g/l, yeast nitrogen base without
amino acids 6.7 g/l and galactose 200 g/l. Amino acids were added
(2 mg/ml) as required. Yeast nitrogen base, yeast extract, peptone and
agar were obtained from Difco Laboratories Inc. (Detroit, MI). Glucose
and galactose were obtained from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Plasmids and cell culture conditions
The plasmid used (pYES2-CPT2) was a generous gift from Dr. F.
Taroni, Milano, Italy [12]. Conﬁrmation of the sequence was achieved
by direct sequencing which showed a correct insertion into the pYES2
vector of the complete open reading frame of the human CPT2,
including the region coding for the corresponding mitochondrial
targeting signal. Transformation of the Δcat2 and Δfox2mutants with
the pYES2-CPT2 plasmid was performed using the lithium acetate
method, as described elsewhere [13]. Transformed cells were
harvested by centrifugation, spread on 3 g/l YNBD plates containing
amino acids as required and cultured for 2 days at 28 °C.
2.3. Growth conditions and preparation of yeast homogenates
Cellswere grownonminimal 20 g/l glucosemediumfor at least 24 h
at 225 rpmand 28 °C in a gyro shaker and then shifted by centrifugation
to galactose medium. Cells from overnight cultures grown on galactosemedium were harvested and treated with zymolyase as described
elsewhere [14]. The resulting protoplasts were homogenized by
sonication (three times, 10 s at 8 W) on ice and suspended in PBS
with Completemini tablets containing a cocktail of protease inhibitors
(Roche; Basel, Switzerland). Protein concentration of the yeast homo-
genateswasdeterminedusing thebicinchoninic acid assay (BCA, Sigma-
Aldrich) [15] and human serum albumin as a reference substance.
2.4. Acyl-CoA esters preparation
Trans-2-dodecenoyl-CoA (C12:1-CoA) and trans-2-hexadecenoyl-
CoA (C16:1-CoA), were enzymatically synthesized from the
corresponding saturated CoA esters using acyl-CoA oxidase. Cis-5-
tetradecenoyl-CoA (C14:1-CoA) was synthesized as described by
Rasmussen et al. [16]. Pristanoyl-CoA, 4,8-dimethylnonanoyl-CoA and
2,6-dimethylheptanoyl-CoA were synthesized by Prof. Dr. G. Dacre-
mont, Belgium. All other CoA esters were obtained from Sigma-Aldrich.
2.5. Determination of carnitine palmitoyltransferase 2 activity using
different acyl-CoA esters
Carnitine palmitoyltransferase 2 activity was determined using the
method described by van Vlies et al. [17]. The standard mixture
contained 150 mM potassium chloride, 25 mM Tris–HCl pH 7.4, 2 mM
EDTA, 10 mM potassium phosphate buffer pH 7.4, 1 mg/ml bovine
serum albumin (BSA) essentially fatty acid free, 500 μM L-carnitine and
25 μM of each acyl-CoA ester to a ﬁnal volume of 150 μl. The reaction
was initiated by the addition of 20 μl of sample (S. cerevisiae
homogenate) and was allowed to proceed at 37 °C. After 10 min
incubation, the reaction was terminated by adding 750 μl acetonitrile
containing50 pmol d3C3-, 50 pmol d3C8- and 25 pmol d3C16-carnitine
internal standards. After derivatization of the produced acylcarnitines
with 1-propanol/acetylchloride 4/1 (v/v), these intermediates were
quantiﬁed by Electro Spray Ionization TandemMass Spectrometry (ESI-
MS/MS). Negative controls were performed as described above, using
yeast homogenates transformed with the empty vector.
2.6. Inhibition studies upon carnitine palmitoyltransferase 2 activity
The effect of trans-2-C16:1-CoA on CPT2 activity was determined
bymeasuring its activity in the presence of different concentrations of
this compound (0–20 μM) and using C16-CoA as substrate (0–40 μM).
Activity was measured as described above with some modiﬁcations.
After 5 min incubation at 37 °C the reaction was terminated by adding
750 μl acetonitrile containing 100 pmol d3C3-, 100 pmol d3C8- and
50 pmol d3C16-carnitine internal standards. In order to gain 10 times
more sensitivity, the samples were analyzed on UPLC-MS/MSwithout
derivatization.
3. Results
3.1. Determination of carnitine palmitoyltransferase 2 activity using
different acyl-CoA esters
In order to determine the substrate speciﬁcity of human CPT2, we
transformed theΔcat2 S. cerevisiaemutant (BY4742 cat2::KAN) with a
plasmid expressing human CPT2 (see Section2.2). This mutant has no
carnitine acetyltransferase activity (cat2, converting acetyl-CoA into
acetylcarnitine). Immunoblot analysis after subcellular fractionation
on Nycodenz gradient showed that the protein is localized in the
mitochondria, although not fully processed to maturity (results not
shown). More important, the heterologously expressed human CPT2
is in its active form and thus used for subsequent kinetic measure-
ments. The results depicted in Fig. 1A show that CPT2 is well
expressed and is active towards medium (C8–C12) and long-chain
(C14–C18) acyl-CoA esters. Virtually no activity was foundwith short-
Fig. 1. CPT2 activitywith straight-chain acyl-CoA esters (A), unsaturated intermediates (B),
C16 mFAO intermediates (C) and peroxisomal products and intermediates (D). The
reactionsweremeasured at 37 °C for 10 min in a standard incubationmediumdescribed in
Materials and methods with L-carnitine and 25 μM of each acyl-CoA ester. The produced
acylcarnitines were quantiﬁed after derivatization with 1-propanol/acetylchloride by ESI-
MS/MS. For additional experimental details see Materials and methods. Data shown are
mean±S.D. of duplicates of at least two independent experiments.
Table 1
Evaluation of CPT2 activity with acyl-CoAs formed upon branched-chain amino acids
oxidation. Activity is expressed as percentage of control (C16-CoA was used as a control
substrate).
CoA-ester CPT2 activity (% of control)
C16-CoA 100
Isovaleryl-CoA b0.1
Isobutyryl-CoA b0.1
Acetoacetyl-CoA b0.1
DL-3-Hydroxybutyryl-CoA b0.1
3-Hydroxyisobutyryl-CoA b0.1
2-Methylacetoacetyl-CoA b0.1
Methylcrotonyl-CoA b0.1
Glutaryl-CoA b0.1
3-Hydroxy-3-methylglutaryl-CoA b0.1
2-Methylbutyryl-CoA b0.1
2-Methyl-3-hydroxybutyryl-CoA b0.1
Table 2
Kinetic constants and catalytic efﬁciency (Vmax/Km) of CPT2 with C16:0-CoA and trans-
2-C16:1-CoA as substrates. The reactions were measured at 37 °C for 5 min in a
standard incubation medium described in Materials and methods with different
concentrations of the acyl-CoA esters. The produced acylcarnitines were quantiﬁed
after derivatization with 1-propanol/acethylchloride by ESI-MS/MS. Values were
calculated from Lineweaver–Burk plots (not shown).
C16:0-CoA trans-2-C16:1-CoA
Km
app (μM) 7.1 8.1
Vmax
app (pmol/min.mg) 1156 77
Vmax/Km 163 9.5
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showed activity towards the cis-5 and cis-9 unsaturated acyl-
CoAs tested (Fig. 1B) and the mitochondrial β-oxidation intermedi-
ates 3-OH and 3-keto-palmitoyl-CoA (Fig. 1C). Surprisingly, different
trans-2-enoyl-CoA, which are intermediates of mFAO, including trans-
2-C16:1-CoA and trans-2-C12:1-CoA, were found to be poor sub-
strates for CPT2. We observed that trans-2-C16:1 and trans-2-C12:1-
CoA intermediates show 1.5% and 1% activity respectively when
compared with the straight-chain acyl-CoAs intermediates of the
same chain-length (C16-CoA and C12-CoA). In the samemanner, only
a small percentage of activity (approximately 1.5%) was found when
comparing with other enoyl substrates (cis-5 and cis-9-C14:1-CoA)
(Fig. 1B).
Breakdown of different amino acids including the branched-chain
amino acids also involves CoA esters. When tested, none of these acyl-
CoAs were found to be a substrate for CPT2 (see Table 1).
Intermediates from peroxisomal fatty acid β-oxidation, namely 4,8-
dimethylnonanoyl-CoA (DMN-CoA), 2,6-dimethylheptanoyl-CoA
(DMH-CoA) and pristanoyl-CoA (Prist-CoA), were also investigated
as potential substrates for CPT2. Interestingly, CPT2 was found to be
active with DMN-CoA which is in line with data in literature [18],
whereas virtually no activity was found with the substrates
pristanoyl-CoA or DMH-CoA (Fig. 1D).3.2. Determination of the enzymatic kinetic parameters of CPT2
Inorder to resolvewhether trans-2-enoyl-CoAsmayact as inhibitorsof
CPT2 activity, we determined the kinetic parameters of CPT2 (Km and
Vmax) using C16-CoA and trans-2-C16:1-CoA as substrates. Employing the
Lineweaver–Burk linearization of the Michaelis–Menten equation, we
found that although trans-2-C16:1-CoA and C16-CoA have approximately
the same afﬁnity for CPT2 (Km(C16-CoA)=7.1 μMandKm(trans-2-C16:1-CoA)=
8.1 μM), the catalytic efﬁciency (here expressed as the ratio Vmax/Km) for
C16-CoA is approximately 20-fold higher than for trans-2-C16:1-CoA
(Table 2). These results indicate that trans-2-enoyl-CoAs might act as
inhibitors of CPT2.
3.3. Inhibition studies with trans-2-C16:1-CoA
To verify if trans-2-C16:1-CoA may act as an inhibitor of the
conversion of acyl-CoA esters into carnitine derivatives catalyzed by
CPT2, inhibition studies were performed in the Δfox2 S. cerevisiae
mutant (BY4742 fox2::KAN) transformed with the plasmid described
in Section2.2 fromMaterials and methods. This mutant lacks 2-enoyl-
CoA hydratase activity (fox2, converting trans-2-enoyl-CoA esters into
L-3-hydroxyacyl-CoA esters). The results shown for each concentra-
tion of inhibitor reveal a small variation (6%) concerning the Vmax
while an increase of approximately 30% in the Km is observed. This
suggests that trans-2-C16:1-CoA acts as a competitive inhibitor of
CPT2 with a Ki of 18.8 μM (Fig. 2 and Table 3).
4. Discussion
The work described in this paper clearly shows that CPT2,
when operating in the reverse direction (acyl-CoA+carnitine→
acylcarnitine+CoA), accepts, at least in vitro, a range of different
mediumand long-chain straight-chain acyl-CoAs (Fig. 1A) and converts
them into the respective acylcarnitines. These results are in agreement
with the data reported by Schaefer et al. [11] in permeabilized human
ﬁbroblasts. In this model of study the substrate speciﬁcity of a malonyl-
CoA insensitive acyltransferase, identiﬁed as CPT2, differs to some
Fig. 2. Evaluation of CPT2 activity using C16-CoA as substrate (0 to 40 μM) in
the presence of trans-2-C16:1-CoA. Inhibition studies were performed with 0 to 40 μM
of trans-2-C16:1-CoA in the presence of 0,1% BSA. A) Non-linear regression;
B) Lineweaver–Burk (0 μM; 5 μM; 10 μM; 20 μM trans-2-C16:1-CoA). The reactions
were measured at 37 °C for 5 min in a standard incubation medium described in
Materials and methods. The produced acylcarnitines were quantiﬁed by UPLC-MS. For
additional experimental details see Materials and methods. Non-linear regression
analysis was performed using the Berkley Madonna™ software.
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According to these authors, CPT2 shows higher activity with substrates
ranging from C8 to C16-CoA with C12-CoA as the preferred substrate
followed by C8-CoA, which was also recognized as the preferred
substrate for the recombinant rat liver CPT2 studied by Johnson et al.
[19]. Our results, however, show that CPT2 has speciﬁcity towards
longer acyl-CoA esters ranging fromC8 to C20-CoAwith C10 to C14-CoA
as thepreferred substrates (Fig. 1A),which compareswell previous dataTable 3
Kinetic parameters Km and Vmax of CPT2 for C16:0-CoA as substrate with different trans-
2-C16:1-CoA concentrations. The Ki value for CPT2 with trans-2-C16:1-CoA was
18.8 μM. The reactions were measured at 37 °C for 5 min in a standard incubation
medium described in Materials and methods with C16:0-CoA from 0 to 40 μM. The
produced acylcarnitines were quantiﬁed by UPLC-MS. Values were calculated from
non-linear regression plots using the Berkley Madonna™ software.
Trans-2-C16:1-CoA
0 μM 5 μM 10 μM 20 μM
Km
app (μM) 7.1 11.6 13.5 15.0
Vmax
app (pmol/min.mg) 1156 1175 1120 1004on CPT2 in bovine liver mitochondria [20], chick embryo liver [21] and
beef heart [22].
Concerning the possible conversion of mFAO intermediates into
their corresponding acylcarnitine esters by CPT2 we observed that
this enzyme accepts different mFAO intermediates as substrates,
including 3-OH and 3-keto acyl-CoA esters, though less efﬁciently
(Fig. 1C). Nevertheless, trans-2-enoyl-intermediates were found to be
poor substrates for the enzyme which suggests that CPT2 may not be
as active towards trans-2-enoyl-CoAs as shown for the other mFAO
intermediates or other unsaturated acyl-CoA esters (Fig. 1B). This data
is consistent with our previous work using puriﬁed human CPT2
protein [10]. The trans double bond in the trans-2-enoyl-CoA esters
may cause a spatial constraint in the binding of these intermediates to
the active site of the enzyme causing the reaction to occur slower than
with other substrates. These ﬁndings may well explain the fact that
trans-2-enoyl-carnitine intermediates have never been reported
neither in plasma nor in ﬁbroblasts acylcarnitine proﬁles from
patients with mFAO disorders [8]. The catalytic efﬁciency of CPT2
with the substrates trans-2-enoyl-CoAs is much lower than when
handling the substrate palmitoyl-CoA (Table 2) and therefore the
reaction is expected to proceed very slowly. Accordingly, enoyl
intermediates were found to act as competitive inhibitors of CPT2
activity ( Fig. 2; Table 3). This may lead to the accumulation of such
intermediates within the mitochondrial matrix in speciﬁc mFAO
deﬁciencies, which would block further clearance of other toxic acyl-
CoA species accumulating in these disorders. Trans-2-enoyl-CoAs are
known toxic intermediates [23–25] which are expected to accumulate
intramitochondrially in mitochondrial trifunctional protein (MTP)
and long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deﬁcien-
cies. In addition to the symptoms usually observed in all mFAO
disorders, MTP and LCHAD deﬁcient patients also present severe
characteristic symptoms including neurological and ophthalmological
manifestations (peripheral neuropathy and retinopathy) and serious
maternal complications during pregnancy [25–28]. It is unlikely that
such severe abnormalities result from the simple accumulation of
long-chain intermediates as they do not emerge in patients suffering
from other long-chain mFAO disorders such as a deﬁciency in very
long-chain acyl-CoA dehydrogenase (VLCAD) [29]. Such clinical facts
suggest different pathological mechanisms underlying these disor-
ders. This may in part be explained by the potential inhibition of CPT2
by trans-2-enoyl-CoAs which only accumulate in MTP and LCHAD
deﬁciencies.
CPT2 activity was also evaluated with some peroxisomal FAO
substrates and intermediates. Only 4,8-dimethylnonanoyl-CoA (DMN-
CoA) shows reactivity with the enzyme (Fig. 1D). This is in line with the
pristanic acid degradation route, where the ﬁrst steps are known to take
place in the peroxisome [18]. Peroxisomal degradation of pristanic acid
proceeds for three cycles of β-oxidation yielding the intermediate DMN-
CoA, probably converted by carnitine octanoyltransferase into the
respective carnitine ester [30] and further exported into the cytoplasm.
Further oxidation requires the mitochondrial import of DMN-carnitine
and its conversion back into DMN-CoA. One additional cycle of β-
oxidation in mitochondria then leads to the formation of 2,6-dimethyl-
heptanoyl-CoA (DMH-CoA) [31]. The metabolic fate of DMH-CoA is not
known [31] but its destiny, according to our results, does not entail its
conversion to the corresponding carnitine ester, at least as catalyzed by
CPT2. The importance of these data for the in vivo situation remains to be
resolved especially since neither DMN nor DMH carnitine derivatives
have ever been reported among the acylcarnitine proﬁles of any mFAO
defect whose block should lead to the concomitant accumulation of
mitochondrially metabolized peroxisomal FAO intermediates.
Also several acyl-CoA esters formed during branched-chain amino
acid oxidation were tested and were not found to be substrates for
CPT2. The presence of the corresponding carnitine intermediates
suggests that these may be formed by the action of other transferases,
including carnitine acetyltransferase (CRAT). A more detailed study
732 S. Violante et al. / Biochimica et Biophysica Acta 1802 (2010) 728–732on the substrate speciﬁcity of CRAT is lacking in literature, thus
requiring further investigation in future work.
5. Conclusions
In summary although acylcarnitines have been recognized over the
last years as important biomarkers for the early detection of mitochon-
drial [32–37] and peroxisomal [18] fatty acid oxidation disorders,
peroxisomal biogenesis defects [38] and branched-chain amino acid
oxidationdisorders [32] andacylcarnitineproﬁling inbloodallowsa rapid
and effective screening of the aforementioned inborn errors of metab-
olism, the studies presented here clearly demonstrate that the proﬁle of
acylcarnitines as observed in plasma may not reﬂect the proﬁle of acyl-
CoA species which accumulate within the mitochondrial matrix under
certain conditions, at leastnot fully. If an intermediate containinga trans-2
double bond accumulates intramitochondrially, the respective carnitine
esters might be missed in the diagnosis. Hence, the data gathered in the
present paper support the rationale for the relevance of determining
mitochondrial acyl-CoA esters proﬁle [39]. Undoubtedly this approach
may be crucial for the elucidation of the diagnosis and further treatment
of mFAO disorders as well as for the understanding of the pathogenic
mechanisms involved in these inborn errors of metabolism.
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